PepLib key facts
as of Oct 2026- Developer of peptide-leading drugs intended to serve the medical sector in China.
- PepLib is valued at approximately $86.1M as of Oct 2026 (last reported valuation).
- It has raised $62.1M; the latest was Later Stage VC ($13.9M) in Jul 2025.
- Notable investors include Cowin Capital, Fortune Capital, CDH Investments, Legend Star, CAS Investment Management — 16 tracked in total.
- Status: Privately Held (backing).
PepLib's last reported valuation, Jul 2019. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch PepLib: the Monday email on marks, rounds and moves
PepLib funding rounds
No funding rounds for PepLib are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs PepLib
16+PepLib valuation
PepLib's last reported valuation was $86.1 million in Jul 2019. No priced round, secondary trade or fund mark has surfaced since.
PepLib investors
16 investors are on record for PepLib, including Cowin Capital, Fortune Capital, CDH Investments and Legend Star. By type, the record holds 5 venture capital firms and 1 private equity firm.
About PepLib
Developer of peptide-leading drugs intended to serve the medical sector in China. The company is platform-based, specialized in the discovery of peptide-leading drugs, focusing on development, production, sale of large-capacity peptide libraries and development of technical services for the screening of new peptides.
- Sector
- Healthcare
- HQ
- Zhuzhou, China
- Founded
- 2017
- Employees
- 200
- Website
- peplib.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.